We identify here for the first time the low-affinity CYP isoforms that metabolize paroxetine, using cDNA-expressed human CYPs measuring substrate depletion and paroxetine-catechol (product) formation by liquid chromatography tandem mass spectrometry. CYP1A2, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 were identified as paroxetine-catechol-forming CYP isoforms, and CYP2C19 and CYP2D6 were identified as metabolizing CYP isoforms by substrate depletion. Michaelis-Menten constants K m and V max were determined by product formation and substrate depletion. Using selective inhibitory studies and a relative activity factor approach for pooled and single-donor human liver microsomes, we confirmed involvement of the identified CYP isoforms for paroxetine-catechol formation at 1 and 20 µM paroxetine. In addition, we used the population based simulator Simcyp® to estimate the importance of the identified paroxetine metabolizing CYP isoforms for human metabolism taking mechanism based inhibition into account. The amount of active hepatic CYP2D6 and CYP3A4 (not inactivated by mechanism based inhibition) was also estimated by Simcyp®.
Introduction
Paroxetine is a selective serotonin reuptake inhibitor used for the treatment of depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, and social anxiety disorder. It is extensively metabolized in humans and exhibits non-linear kinetics (Haddock et al., 1989; Kaye et al., 1989) . After administration of a single dose of paroxetine, poor metabolizers (PMs) and extensive metabolizers (EMs) of CYP2D6 display a 7-fold difference in the median total clearance. Under steady-state (SS) conditions, this difference falls dramatically to 2-fold. Non-linear paroxetine kinetics is more prominent in EMs of CYP2D6 than PMs of CYP2D6 (Sindrup et al., 1992a; Sindrup et al., 1992b ). Fig. 1 shows the major reported CYP metabolic pathways. CYP2D6 catalyzes demethylation of the methylenedioxy group, presumably yielding paroxetine-catechol (Haddock et al., 1989) and formate (Bloomer et al., 1992) . The paroxetine-catechol metabolite is described as an unstable intermediate (Kaye et al., 1989) . Catechol-O-methyltransferase (COMT) enzymes methylate paroxetine-catechol (Maurer et al., 2000) , yielding metabolites I and II. In humans, metabolites I and II are found as the conjugated glucuronide or sulfate conjugates in urine, with metabolite I as the main metabolite (Haddock et al., 1989) . CYP2D6 has been identified as a high-affinity paroxetine-metabolizing enzyme, and because PMs of CYP2D6 also metabolize paroxetine, a low-affinity CYP isoform or CYP isoforms must exist that have yet to be identified (Bloomer et al., 1992; Sindrup et al., 1992a; Sindrup et al., 1992b) .
Paroxetine is a mechanism-based inhibitor of CYP2D6 (Bertelsen et al., 2003) and CYP3A (Obach et al., 2007) . The mechanism-based inhibition (MBI) is most likely caused by an irreversible binding of a paroxetine-reactive metabolite, one that does not leave the active site, to the heme complex in the CYP enzyme (Bertelsen et al., 2003; Zhao et al., This article has not been copyedited and formatted. The final version may differ from this version. . The MBI kinetic constants (K inact , K I ) have been determined for CYP2D6 and CYP3A (Bertelsen et al., 2003; Obach et al., 2007) . With the MBI kinetic constants for CYP2D6 and the EM data from Sindrup et al. (1992b) , Venkatakrishnan and Obach (2005) used in vitro/in vivo extrapolation (IVIVE) to successfully predict the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine. Sindrup et al. observed a 5-fold decrease in clearance under SS conditions compared to the single-dose situation for EMs of CYP2D6 (1992b). All of this points towards the MBI of CYP2D6 as an explanation, one that is further supported by the lack of decrease in clearance from single dose to SS conditions for the PMs of CYP2D6 (Sindrup et al., 1992b) .
To our knowledge, the identity of the low-affinity paroxetine-metabolizing CYP isoform(s) remains unknown, but indirect evidence from Kuss and Hegerl (1998) points to involvement of CYP3A4; they found that patients co-medicated with carbamazepine (a CYP3A4 inducer) had about half the paroxetine concentration levels of patients not treated with carbamazepine. This is supported by results from van der Lee et al (2007) who state that combing phenytoin (a CYP3A4 inducer) with paroxetine decreased paroxetine levels. These inferences are also supported by the finding that paroxetine is a weak MBI of CYP3A (Obach et al., 2007) , especially given that the reactive species most likely does not leave the active site before inactivation (Zhao et al., 2007) , also suggesting involvement of CYP3A4 in paroxetine metabolism.
The objective of the present study was to identify additional CYP isoforms that metabolize paroxetine and estimate their kinetic parameters. We investigated 11 CYP isoforms for paroxetine metabolic capability in vitro by substrate depletion and paroxetinecatechol (product) formation. The kinetic parameters K m and V max of the metabolizing CYP isoforms were estimated by paroxetine depletion and product formation; such information is sparsely available in the literature and exists only for CYP2D6. Using selective inhibitor This article has not been copyedited and formatted. The final version may differ from this version. 6 studies in human liver microsomes (HLMs) and comparing the results to those obtained using a relative activity factor (RAF) approach, we investigated the validity of the obtained kinetic parameters. Finally, in order to estimate the importance of the CYP isoforms for human paroxetine metabolism an IVIVE of paroxetine metabolism was performed using the population-based simulator Simcyp® to generate pharmacokinetic simulations that incorporate aspects of MBI. These pharmacokinetic simulations were compared with existing in vivo pharmacokinetic data for paroxetine to validate the simulations in EM and PM CYP2D6 population groups. Comprehensive identification of the CYP isoforms involved in the metabolism of paroxetine, estimation of their kinetic parameters, and subsequent integration into a physiologically based pharmacokinetic model such as Simcyp® will provide a platform for a better fundamental understanding of paroxetine pharmacokinetics in vitro as well as in the clinic.
Waldbronn, Germany) liquid chromatography (LC) system with an HTC PAL autosampler (CTC Analytics, Zwingen, Switzerland) and an Applied Biosystems API 4000 (MDS Sciex, Concord, Ontario, Canada) tandem mass spectrometry (MS/MS) system using Analyst 1.4.2 software. The analytical column was a Waters (Waters, Millford, MA, USA) XTerra C18 (2.5 µm, 20 × 2.1 mm) operated at 60°C. The gradient consisted of 0.1% formic acid in a 95/5% water/acetonitrile solution (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) at a flow rate of 0.8 ml/min, 0.00-0.50 min (0 95% B), 0.50-1.00 min (95% B), 1.00-1.10 min (95 0%B), and 1.10-2.00 min (0% B). The injected sample volume was 10 µl. The mass spectrometer was operated in positive electrospray mode with a 5-kV ionization potential and an ion source temperature of 600°C. The analytes were quantified in multiple reaction-monitoring mode. The mass transitions used were m/z: paroxetine (330.10 70.20) and paroxetine-D6 (336.00 76.10). Dwell time was 30 ms. The internal standard was 0.22 µM paroxetine-D6 (internal standard to paroxetine) dissolved in acidic acetonitrile (30 µl formic acid per 10 ml acetonitrile). Calibration standards at six levels (0.01, 0.05, 0.24, 1.2, 6.1, and 30.4 µM) were prepared daily by addition of stock solution of paroxetine (3150 µM) to the acidic reaction mixture (30 µl formic acid per 10 ml reaction mixture) for serial dilutions. Calibration standards were analyzed in duplicate, and quality control samples at four levels were run daily (paroxetine concentrations of ~0.02, ~0.1, ~1, and ~5 µM) and checked to confirm that they were at the nominal value, as was the paroxetine concentration in the assay. Nonlinear regression and statistical analysis were done with GraphPad Prism 5.00 (La Jolla, CA, USA). Nonlinear regression was used to evaluate whether a straight line or a quadratic curve was the best calibration model using 1/x weighting. MassLynx 4.1 software. The analytical column was a Waters Xbridge C18 2.5 µm 2.1 × 50 mm operated at 50°C. The solutions for the gradient were as described above; the gradient was 0.0-0.1 min (0 28% B), 0.1-1.0 (28 35% B), 1.0-2.0 min (35 90% B), 2.0-2.5 min (90% B), 2.5-2.6 (90 0 %B), and 2.6-5.0 (0% B). The flow was 0.4 ml/min, and the injection volume was 10 µl. The mass spectrometer was operated in positive electrospray mode with a 3-kV ionization potential and an ion source temperature of 500°C. The analytes were quantified in multiple reaction-monitoring mode. The mass transitions used were m/z: paroxetine-catechol (318.06 70.00), Z-10-OH-amitriptyline (294.30 57.80), paroxetine (330.06 70.00), and paroxetine-D6 (336.06 76.00). Dwell time was 150 ms. The internal standards were 0.34 µM Z-10-OH-amitriptyline (internal standard to paroxetine-catechol) and 0.22 µM paroxetine-D6 (internal standard to paroxetine) dissolved in acetonitrile containing 30 µl formic acid per 10 ml acetonitrile and 2 mM ascorbic acid. Calibration standards at six levels for catechol (0.0015, 0.0030, 0.015, 0.073, 0.37, 1.85 µM) and seven levels for paroxetine (0.004, 0.008, 0.043, 0.21, 1.06, 5.3, 26 .6 µM) were prepared daily by serial dilution of stock solutions of paroxetine (3150 µM) and paroxetine-catechol (1019 µM) added to 0.1 mM phosphate buffer (as described above) containing 30 µl formic acid per 10 ml phosphate buffer and 1 mM ascorbic acid. All quantifications were done so that the samples for the calibration curve had the same matrix (except the NADPH-regenerating system) as the assay samples for quantification. Calibration standards were analyzed in duplicate, and quality control samples containing both paroxetine and paroxetine-catechol at four levels were run daily and checked for confirmation that they were at their nominal value, as was the concentration of paroxetine in the assay. Nonlinear regression was used to evaluate whether a straight line or a quadratic curve was the best calibration model using 1/x weighting. 
LC/MS/MS
This article has not been copyedited and formatted. The final version may differ from this version. The background paroxetine-catechol formation was subtracted from both the inhibited and the control samples. Quinidine was added to background formation samples for quinidine experiments because quinidine has an indirect antioxidant property (Chattopadhyay et al., 2003) . Inhibitory antibodies to CYP2C19 were preincubated with the microsomes for 20 min in an ice bath; controls were preincubated with 4 µL Tris buffer per 100 µg HLM protein according to the instructions from BD Gentest. Furafylline was preincubated 15 min at 37ºC
with the microsomes before starting the assay by addition of paroxetine.
Specific Inhibitor Efficacy.
To assure adequate inhibition of the target CYP isoenzymes, the selected inhibitor concentrations were checked with cDNA-expressed CYP isoenzymes at the aforementioned concentrations and a total paroxetine concentration of 1 and 20 µM with an incubation time of 5 min.
Prediction of Relative Paroxetine-Catechol Formation Contributions in HLMs.
The relative contribution of the identified paroxetine-catechol-forming CYP isoforms in HLMs were predicted using RAFs (Crespi and Miller, 1999; Venkatakrishnan et al., 2000a) :
, where f i is the relative contribution of a specific CYP isoform, RAF i is the relative activity factor, and v i is the reaction velocity of the CYP isoform at a specific paroxetine concentration calculated by eq. 4 or 6 using the estimated V max and unbound K m and K s using the free concentration of paroxetine. RAFs were calculated by eq. 9, using the supplier's info sheets of probe substrate turnover rates in cDNA-expressed CYPs and HLMs. The probe substrates were: phenacetin deethylase activity (CYP1A2), (S)-mephenytoin 4'-hydroxylase Substrate Depletion Screening Studies.
Of the 11 CYP isoforms tested, paroxetine depletion was seen for CYP2D6 and CYP2C19, as was a low depletion capability for CYP3A4.
Paroxetine-Catechol Formation Screening Studies. There was a significant formation of paroxetine-catechol by CYP1A2, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and pHLM.
Other CYP isoforms and human liver cytosol formed paroxetine-catechol comparable to background formation in ICCs.
Substrate Depletion Kinetic Studies. K m and V max by the substrate depletion method (eq. 2) could be estimated only for CYP2D6 and CYP2C19. There was an approximately 20-40% background depletion of paroxetine in the ICC control. Fig. 2 shows K dep plots corrected for this background depletion, and Table 2 Fig. 3 shows the MM plots, with and without substrate inhibition, for the CYPs, and Table 2 shows the best-fit values of K m , K s , and V max by nonlinear regression according to eq. 4 or eq. 6. For pHLM, biphasic kinetics (eq. 5) was the best model (p < 0.01), and MM kinetics (eq. 4) was the best model for PM CYP2D6 sdHLM(1). Fig. 3 shows the corresponding two-site binding model plot for pHLM and the MM plot for sdHLM(1), and Table 2 shows the best-fit values.
Specific Inhibitor Efficacy. Specific inhibition results (inhibitor, CYP inhibited, %
inhibition at 1 or 20 µM paroxetine, respectively) are as follows: 5 µM quinidine, CYP2D6, 86%, 98%; 0.5 µM ketoconazole, CYP3A4, 87%, 91%; 10 µM furafylline, CYP1A2, 75%, 93%; and MAB 2C19, CYP2C19, 95%, 95%.
Role of Individual CYP Isoforms in HLM. Table 3 Table 4 gives the predicted relative contributions of the paroxetine-catechol-forming CYP isoforms (CYP1A2, CYP2C19, CYP2D6, and CYP3A4) using the RAF approach (eq. 8 and eq. 9) for the different HLMs. The RAF predictions were made at 0.4 and 8 µM unbound paroxetine concentrations (corresponding to total concentrations of 1 and 20 µM). CYP3A5 was not included for the RAF calculations, but considering the large K m of CYP3A5, the contribution would be minimal.
Simcyp® Simulations. Table 5 presents the oral clearances calculated by Simcyp® using kinetic constants estimated from paroxetine-catechol formation, and literature values. Table 6 shows the contribution of the CYP isoforms to hepatic metabolism. 
Discussion
The objective of this work was to identify the CYP isoforms that have paroxetine metabolic capability. According to the literature (Kaye et al., 1989), paroxetine-catechol is an unstable metabolite. In the present study, the metabolite was stabilized by addition of SOD to the in vitro assay, lowering the pH when the assay is stopped (catechols are more stable at low pH), and by addition of ascorbic acid. Using paroxetine-catechol formation, we identified the previously reported CYP isoform CYP2D6 and thus far unreported CYP isoforms CYP1A2, CYP2C19, CYP3A4, and CYP3A5 as paroxetine-metabolizing CYP isoforms. This study therefore confirmed that formation of paroxetine-catechol is an important metabolic pathway for paroxetine. We acknowledge that the kinetic parameters estimated with substrate depletion in this study are far from perfect, but we find it important to show these results because This article has not been copyedited and formatted. The final version may differ from this version. and 167 pmol/mg/min at 7.5 µM paroxetine. For the pHLM in the current study, the corresponding paroxetine-catechol formation rates at these free concentrations were 60 and 114 pmol/mg/min. This result is in the same range as that of Bloomer et al., considering the potential differences between the pHLM and the use of one EM CYP2D6 liver.
We note the Cl int for CYP2D6, which is quite large. For a perfect enzyme, an enzyme in which every collision of substrate and enzyme would result in the formation of an enzyme-substrate complex, Cl int is larger by a factor of approximately 20-200 (Mathews and Van Holde, 1996) . From this, we obtain an indication of how effective CYP2D6 is in The f u -corrected K m for the CYP enzymes could be over-or underestimated because binding to the ICM could be different than binding to HLM; e.g., the binding of amitriptyline to human b-lymphoblastoid cells is lower than to HLM (Venkatakrishnan et al., 2000b) . For the in vitro assay of paroxetine-catechol formation, there was background paroxetine-catechol formation (0.1% of total paroxetine concentration). This could be an in vitro artefact or in fact a metabolic contribution, and it cannot be excluded that there is a spontaneous element of paroxetine metabolism in vivo, but we did not attempt such an estimation here.
This article has not been copyedited and formatted. The final version may differ from this version. For the SS situation, with CYP2D6 to a large degree and CYP3A4 to a lesser degree inactivated because of MBI, CYP3A4, CYP1A2, and CYP2C19 will become more important for the metabolism. Using Simcyp® for IVIVE, we incorporated the aspect of MBI into the assessment of the importance of the CYP isoforms for human metabolism of paroxetine. With the estimated kinetic constants by paroxetine-catechol formation for the CYP isoforms the Simcyp® estimated oral clearances were generally within a 2-3-fold error margin compared to the literature values (Table 5) Table 6 shows the relative importance of the CYP isoforms for hepatic paroxetine metabolism. For EM of CYP2D6 in the single dose situation CYP2D6 is the major metabolizing isoform (median 98% contribution), but at SS conditions the importance is reduced to 44%. For comparison the importance of CYP3A4 increases from 2 to 35%. For PM of CYP2D6 CYP3A4 is the major metabolizing CYP isoform for single dose and SS situation. CYP2C19 and CYP3A5 are not of any major importance for the metabolism, whereas CYP1A2 might be of importance in certain individuals as seen from the ranges in Table 6 . These findings clearly show how the incorporation of MBI into the IVIVE model is of high importance to estimate the relative importance of the CYPs for paroxetine metabolism. In Table 7 the Simcyp® predicted effect of MBI on the active hepatic CYP2D6
and CYP3A4 is given. The active amount of CYP2D6 is reduced from a median 87% to 2%
This article has not been copyedited and formatted. The final version may differ from this version. comparing single dose to SS conditions. However the 2% active CYP2D6 is still enough for CYP2D6 to be a major metabolizing enzyme at SS. For CYP3A4 the effect of MBI is most profound for PM of CYP2D6 where the median active percentage is reduced from 97% to 60% at SS conditions. There is solid evidence in the literature of the reduced CYP2D6 activity in chronic dosing with paroxetine e.g. Laine et al. (2001) and Solai et al. (2002) . Table 8 shows the Simcyp® predicted median active percentage hepatic CYP2D6 and CYP3A4 at different dosing levels for EM of CYP2D6. For CYP3A4 it is predicted that the activity is reduced by 40% at 50 mg paroxetine daily dosing. Paroxetine interaction studies with alprazolam (Calvo et al., 2004) and terfenadine (Martin et al., 1997) showed no interaction with paroxetine at chronic dosing. This is expected at the used dosing of 20 mg paroxetine daily which would give a very limited inhibition of CYP3A4 of 5% according to the prediction in Table 8 . If the predictions in Table 8 are correct, paroxetine interactions with CYP3A4 are only observable at higher dosing of paroxetine. The estimated percentage active hepatic enzyme in Table 7 and 8 is highly dependent on many parameter values e.g. the half life of the hepatic CYP isoform (in this study CYP2D6 half life=70 h, CYP3A4 half life = 90 h, Simcyp® predefined values) and the estimates for of the kinetic parameter values for MBI.
The results in Table 7 and 8 should be interpreted bearing this in mind.
Considering the kinetic parameters, inhibition results, RAF calculations, and
Simcyp® simulations, CYP2D6 and CYP3A4 are most likely to be the major contributors to paroxetine metabolism in humans. CYP1A2 could be of importance for paroxetine metabolism in some individuals, whereas the importance of CYP2C19 and CYP3A5 is Bloomer et al., 1992; Maurer et al., 2000; Sindrup et al., 1992b) .
a Reported in this study. Table 4 . Predicted part of paroxetine-catechol formation in different HLMs using RAFs a The total paroxetine was corrected by the free fraction for the calculations (f u =0.4) corresponding to 0.4 and 8 µM free concentration.
b The predicted part of paroxetine-catechol formation for CYP2D6 is set to zero because of the PM status (even if probe substrate turnover rate was not zero according to the manufacturer's info sheet). 
